Needham & Company LLC reaffirmed their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY - Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $49.00 target price on the stock.
Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. Mizuho upped their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $52.33.
Check Out Our Latest Research Report on Harmony Biosciences
Harmony Biosciences Stock Performance
Shares of HRMY traded down $0.04 during mid-day trading on Tuesday, hitting $34.05. 527,947 shares of the company's stock were exchanged, compared to its average volume of 587,329. The business's 50 day moving average is $31.38 and its two-hundred day moving average is $34.01. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.96 billion, a P/E ratio of 16.14, a P/E/G ratio of 0.47 and a beta of 0.82. Harmony Biosciences has a fifty-two week low of $26.47 and a fifty-two week high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 earnings per share. On average, equities analysts expect that Harmony Biosciences will post 2.43 earnings per share for the current year.
Institutional Trading of Harmony Biosciences
A number of hedge funds have recently made changes to their positions in HRMY. Financial Management Professionals Inc. bought a new position in Harmony Biosciences during the 1st quarter valued at $29,000. GAMMA Investing LLC boosted its position in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after buying an additional 436 shares during the period. Mendota Financial Group LLC raised its stake in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Harmony Biosciences in the 4th quarter worth approximately $41,000. Finally, KBC Group NV raised its stake in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after buying an additional 819 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.
About Harmony Biosciences
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
See Also

Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.